Chinese General Practice ›› 2020, Vol. 23 ›› Issue (23): 2975-2980.DOI: 10.12114/j.issn.1007-9572.2019.00.794
Special Issue: 肿瘤最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:
2020-08-15
Online:
2020-08-15
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2019.00.794
[1]VALEBERG B T,RUST?EN T,BJORDAL K,et al.Self-reported prevalence,etiology,and characteristics of pain in oncology outpatients[J].Eur J Pain,2008,12(5):582-590.DOI:10.1016/j.ejpain.2007.09.004. [2]XING F F,YONG R J,KAYE A D,et al.Intrathecal drug delivery and spinal cord stimulation for the treatment of cancer pain[J].Curr Pain Headache Rep,2018,22(2):11.DOI:10.1007/s11916-018-0662-z. [3]COHEN S P,DRAGOVICH A.Intrathecal analgesia[J].Anesthesiol Clin,2007,25(4):863-882,Ⅷ.DOI:10.1016 /j.anclin.2007.07.001. [4]PERT C B,SNYDER S H.Opiate receptor:demonstration in nervous tissue[J].Science,1973,179(4077):1011-1014.DOI:10.1126/science.179.4077.1011. [5]ONOFRIO B M,YAKSH T L,ARNOLD P G.Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin[J].Mayo Clin Proc,1981,56(8):516-520. [6]BOTTROS M M,CHRISTO P J.Current perspectives on intrathecal drug delivery[J].J Pain Res,2014,7:615-626.DOI:10.2147/JPR.S37591. [7]DEER T R,POPE J E,HAYEK S M,et al.The Polyanalgesic Consensus Conference(PACC):recommendations for intrathecal drug delivery:guidance for improving safety and mitigating risks[J].Neuromodulation,2017,20(2):155-176.DOI:10.1111/ner.12579. [8]CARVAJAL G,DUPOIRON D,SEEGERS V,et al.Intrathecal drug delivery systems for refractory pancreatic cancer pain[J].Anesth Analg,2018,126(6):2038-2046.DOI:10.1213/ane.0000000000002903. [9]BALLANTYNE J C,CARWOOD C M.Comparative efficacy of epidural,subarachnoid,and intracerebroventricular opioids in patients with pain due to cancer[J].Cochrane Database Syst Rev,2005(1):CD005178.DOI:10.1002/14651858.CD005178. [10]BRUEL B M,BURTON A W.Intrathecal therapy for cancer-related pain[J].Pain Med,2016,17(12):2404-2421.DOI:10.1093/pm/pnw060. [11]National Cancer Institute Office of Cancer Survivorship.Survivorship definition[EB/OL].[2019-07-01].https://www.cancer.gov/publications/dictionaries/cancer-terms/def/survivorship.htm. [12]SYRJALA K L,JENSEN M P,MENDOZA M E,et al.Psychological and behavioral approaches to cancer pain management[J].J Clin Oncol,2014,32(16):1703-1711.DOI:10.1200/JCO.2013.54.4825. [13]DEER T R,PRAGER J,LEVY R,et al.Polyanalgesic Consensus Conference——2012:recommendations on trialing for intrathecal(intraspinal) drug delivery:report of an interdisciplinary expert panel[J].Neuromodulation,2012,15(5):420-435;discussion 435.DOI:10.1111/j.1525-1403.2012.00450.x. [14]GLARE P A,DAVIES P S,FINLAY E,et al.Pain in cancer survivors[J].J Clin Oncol,2014,32(16):1739-1747.DOI:10.1200/JCO.2013.52.4629. [15]DEER T R,SMITH H S,BURTON A W,et al.Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain[J].Pain Physician,2011,14(3):E283-312. [16]STAATS P S,YEARWOOD T,CHARAPATA S G,et al.Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS:a randomized controlled trial[J].JAMA,2004,291(1):63-70.DOI:10.1001/jama.291.1.63. [17]ISHIDA T.Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia[J].Yakugaku Zasshi,2004,124(8):541-547.DOI:10.1248/yakushi.124.541. [18]TARICCO M,ADONE R,PAGLIACCI C,et al.Pharmacological interventions for spasticity following spinal cord injury[J].Cochrane Database Syst Rev,2000(2):CD001131.DOI:10.1002/14651858.CD001131. [19]SMITH T J,COYNE P.What is the evidence for implantable drug delivery systems for refractory cancer pain?[J].Support Cancer Ther,2004,1(3):185-189.DOI:10.3816/SCT.2004.n.011. [20]KNIGHT K H,BRAND F M,MCHAOURAB A S,et al.Implantable intrathecal pumps for chronic pain:highlights and updates[J].Croat Med J,2007,48(1):22-34. [21]HUH B,ROLDAN C J.Magnetic fields and intrathecal pump malfunction[J].Am J Emerg Med,2016,34(1):115.e5-115.e6.DOI:10.1016/j.ajem.2015.04.084. [22]MOHAMMED I,HUSSAIN A.Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump:a case report[J].BMC Clin Pharmacol,2004,4:6.DOI:10.1186/1472-6904-4-6. [23]PADALIA D,JASSAL N,PATEL S.Near Death Experience from Placement of an Intrathecal Catheter[EB/J].[2019-11-01].Pain Physician,2016,19(4):E621-623.https://www.painphysicianjournal.com/current/pdf?article=MjcxOQ%3D%3D&journal=96.htm. [24]TEXTOR L H.CE:intrathecal pumps for managing cancer pain[J].Am J Nurs,2016,116(5):36-44.DOI:10.1097/01.NAJ.0000482955.78306.b1. [25]DUARTE R V,RAPHAEL J H,SOUTHALL J L,et al.Intrathecal granuloma formation as result of opioid delivery:systematic literature review of case reports and analysis against a control group[J].Clin Neurol Neurosurg,2012,114(6):577-584.DOI:10.1016/j.clineuro.2011.12.007. [26]VEIZI I E,HAYEK S M,HANES M,et al.Primary hydromorphone-related intrathecal catheter tip granulomas:is there a role for dose and concentration?[J].Neuromodulation,2016,19(7):760-769.DOI:10.1111/ner.12481. [27]GUPTA A,MARTINDALE T,CHRISTO P J.Intrathecal catheter granuloma associated with continuous sufentanil infusion[J].Pain Med,2010,11(6):847-852.DOI:10.1111/j.1526-4637.2010.00860.x. [28]ALLEN J W,HORAIS K A,TOZIER N A,et al.Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs:a combined magnetic resonance imaging and histopathology investigation[J].Anesthesiology,2006,105(3):581-589.DOI:10.1097/00000542-200609000-00024. [29]ALLEN J W,HORAIS K A,TOZIER N A,et al.Opiate pharmacology of intrathecal granulomas[J].Anesthesiology,2006,105(3):590-598.DOI:10.1097/00000542-200609000-00025. [30]YAKSH T L,ALLEN J W,VEESART S L,et al.Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation[J].Anesthesiology,2013,118(3):664-678.DOI:10.1097/ALN.0b013e31828351aa. [31]CABBELL K L,TAREN J A,SAGHER O.Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy:case report[J].Neurosurgery,1998,42(5):1176-1180;discussion 1180-1.DOI:10.1097/00006123-199805000-00142. [32]ZHANG J,GRUBER B L,MARCHESE M J,et al.Mast cell tryptase does not alter matrix metalloproteinase expression in human dermal fibroblasts:further evidence that proteolytically-active tryptase is a potent fibrogenic factor[J].J Cell Physiol,1999,181(2):312-318.DOI:10.1002/(SICI)1097-4652(199911)181:2<;312::AID-JCP13>;3.0.CO;2-1. [33]GARBUZENKO E,NAGLER A,PICKHOLTZ D,et al.Human mast cells stimulate fibroblast proliferation,collagen synthesis and lattice contraction:a direct role for mast cells in skin fibrosis[J].Clin Exp Allergy,2002,32(2):237-246.DOI:10.1046/j.1365-2222.2002.01293.x. [34]SINGHAL P C,SHARMA P,SANWAL V,et al.Morphine modulates proliferation of kidney fibroblasts[J].Kidney Int,1998,53(2):350-357.DOI:10.1046/j.1523-1755.1998.00758.x. [35]CHEN L,SCHREMENTI M E,RANZER M J,et al.Blockade of mast cell activation reduces cutaneous scar formation[J].PLoS One,2014,9(1):e85226.DOI:10.1371/journal.pone.0085226. [36]AVULA M N,RAO A N,MCGILL L D,et al.Foreign body response to subcutaneous biomaterial implants in a mast cell-deficient Kit(w-Sh) murine model[J].Acta Biomater,2014,10(5):1856-1863.DOI:10.1016/j.actbio.2013.12.056. [37]THEVENOT P T,BAKER D W,WENG H,et al.The pivotal role of fibrocytes and mast cells in mediating fibrotic reactions to biomaterials[J].Biomaterials,2011,32(33):8394-8403.DOI:10.1016/j.biomaterials.2011.07.084. [38]HAYEK S M,VEIZI I E,NAROUZE S N,et al.Age-dependent intrathecal opioid escalation in chronic noncancer pain patients[J].Pain Med,2011,12(8):1179-1189.DOI:10.1111/j.1526-4637.2011.01188.x. [39]DEER T R,PRAGER J,LEVY R,et al.Polyanalgesic Consensus Conference——2012:consensus on diagnosis,detection,and treatment of catheter-tip granulomas(inflammatory masses)[J].Neuromodulation,2012,15(5):483-495;discussion 496.DOI:10.1111/j.1525-1403.2012.00449.x. [40]UPADHYAY S P,MALLICK P N.Intrathecal drug delivery system(IDDS) for cancer pain management:a review and updates[J].Am J Hosp Palliat Care,2012,29(5):388-398.DOI:10.1177/1049909111426134. [41]BHATIA G,LAU M E,KOURY K M,et al.Intrathecal drug delivery(ITDD) systems for cancer pain[J].F1000Res,2013,2:96.DOI:10.12688/f1000research.2-96.v4. [42]COFFEY R J,OWENS M L,BROSTE S K,et al.Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain[J].Anesthesiology,2009,111(4):881-891.DOI:10.1097/ALN.0b013e3181b64ab8. [43]KINSELLA J B,RASSEKH C H,WASSMUTH Z D,et al.Smoking increases facial skin flap complications[J].Ann Otol Rhinol Laryngol,1999,108(2):139-142.DOI:10.1177/000348949910800206. [44]KUMAR K,NATH R,WYANT G M.Treatment of chronic pain by epidural spinal cord stimulation:a 10-year experience[J].J Neurosurg,1991,75(3):402-407.DOI:10.3171/jns.1991.75.3.0402. [45]FJELSTAD A B,HOMMELSTAD J,SORTEBERG A.Infections related to intrathecal baclofen therapy in children and adults:frequency and risk factors[J].J Neurosurg Pediatr,2009,4(5):487-493.DOI:10.3171/2009.6.PEDS0921. [46]National Institute for Health and Care Excellence.Surgical site infection quality standard[QS49][EB/OL].[2019-07-01].https://www.nice.org.uk/guidance/qs49.htm. [47]WALEGA D R,KORN M.Management of a cancer patient with an intrathecal drug delivery system and an acute brain abscess[J].J Palliat Med,2018,21(5):727-729.DOI:10.1089/jpm.2017.0628. [48]NAROUZE S,BENZON H T,PROVENZANO D A,et al.Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications:guidelines from the American Society of Regional Anesthesia and Pain Medicine,the European Society of Regional Anaesthesia and Pain Therapy,the American Academy of Pain Medicine,the International Neuromodulation Society,the North American Neuromodulation Society,and the World Institute of Pain[J].Reg Anesth Pain Med,2015,40(3):182-212.DOI:10.1097/AAP.0000000000000223. [49]FRIZON L A,SABHARWAL N C,MAITI T,et al.Removal of intrathecal catheters used in drug delivery systems[J].Neuromodulation,2018,21(7):665-668.DOI:10.1111/ner.12799. [50]MALDONADO-NARANJO A L,FRIZON L A,SABHARWAL N C,et al.Rate of complications following spinal cord stimulation paddle electrode removal[J].Neuromodulation,2018,21(5):513-519.DOI:10.1111/ner.12643. [51]LIU J K,SOLIMAN H,MACHADO A,et al.Intracranial hemorrhage after removal of deep brain stimulation electrodes[J].J Neurosurg,2012,116(3):525-528.DOI:10.3171/2011.10.JNS11465. [52]LIEBER B A,APPELBOOM G,TAYLOR B E,et al.Preoperative chemotherapy and corticosteroids:independent predictors of cranial surgical-site infections[J].J Neurosurg,2016,125(1):187-195.DOI:10.3171/2015.4.JNS142719. [53]MAINO P,VAN KUIJK S M J,PEREZ R S G M,et al.Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface:a prospective comparison study of ultrasound-guided vs.blind refill technique[J].Neuromodulation,2018.DOI:10.1111/ner.12849. [54]GOFELD M,MCQUEEN C K.Ultrasound-guided intrathecal pump access and prevention of the pocket fill[J].Pain Med,2011,12(4):607-611.DOI:10.1111/j.1526-4637.2011.01090.x. [55]KIM E K,SHIN J Y,CASTA?EDA A M,et al.Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea[J].Korean J Pain,2017,30(4):272-280.DOI:10.3344/kjp.2017.30.4.272. [56]Ottawa Hospital Research Institute,University Of Ottawa,Health Quality Ontario.Intrathecal drug delivery systems for cancer pain:a health technology assessment[EB/OL].[2019-07-01].Ont Health Technol Assess Ser,2016,16(1):1-51.https://www.hqontario.ca/Evidence-to-Improve-Care/Health-Technology-Assessment/Reviews-And-Recommendations/Intrathecal-Drug-Delivery-Systems-for-Cancer-Pain-and-Noncancer-Pain.htm. |
[1] | LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740. |
[2] | ZHU Ting, ZHONG Jinjia, WU Hao, HUANG Yafang. Current Status and Characteristics of Novel Cancer Drugs Approved in China with Clinical Response Rate as a Surrogate Endpoint [J]. Chinese General Practice, 2025, 28(20): 2523-2529. |
[3] | ZHANG Shujing, SUN Lixin, CAO Yuqing. Comparative Study on the Clinicopathological Features and Prognostic between HPV-related and Non-HPV-related Cervical Adenocarcinoma [J]. Chinese General Practice, 2025, 28(14): 1758-1764. |
[4] | YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on 18F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472. |
[5] | ZHANG Yushuang, WU Zhongbing, HUANG Ming, JIA Lei, GAO Shuang, ZHAO Weipeng, LI Jing. Study on Metabolic Characteristics in Esophageal Squamous Cell Carcinoma Patients with TCM Differentiation of Deficiency of Fluid and Blood Based on Non Target Metabolomics [J]. Chinese General Practice, 2025, 28(12): 1513-1519. |
[6] | LYU Cheng, JIANG Sheng. Research Progress on the Relationship between Vitamin D and Type 1 Diabetes Mellitus and Its Complications [J]. Chinese General Practice, 2025, 28(12): 1538-1542. |
[7] | LOU Xianzhe, MIAO Tongguo, ZHANG Shiya, MA Dong, NAN Yuemin. The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral, Non-Alcoholic Hepatocellular Carcinoma: a Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(09): 1092-1099. |
[8] | MA Xiaoxuan, WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment [J]. Chinese General Practice, 2025, 28(08): 1017-1022. |
[9] | SONG Fenfen, LI Shengmian. Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer [J]. Chinese General Practice, 2025, 28(07): 844-852. |
[10] | ZHANG Jin, SUN Di, WANG Hao, SHI Cong, ZHAO Yihan, PAN Yijin, MU Zhuanzhuan, DING Zhiguo, LIN Yansong. Factors Influencing Biochemical Progression in Distant Metastatic Papillary Thyroid Carcinoma [J]. Chinese General Practice, 2024, 27(36): 4546-4553. |
[11] | HE Bangjing, ZHOU Mingwang, ZHANG Pengwei. Mechanism of Estrogen and Estrogen Receptors in Pathologic Pain [J]. Chinese General Practice, 2024, 27(33): 4204-4209. |
[12] | YANG Anyin, LIU Hongli, CHEN Miaoyang, ZHENG Yufeng, XU Zhiyuan, YANG Yongfeng. Mechanism and in Vitro Experiment of Wogonin in Treatment of Hepatocellular Carcinoma Based on Network Pharmacology [J]. Chinese General Practice, 2024, 27(32): 4040-4049. |
[13] | CHEN Chao, CHEN Tianxiang, LIU Qianwei, ZHANG Zhi, WANG Huanhuan, WU Pingping, GAO Lei, YU Zhaoxiang. Analysis and Identification of Hub Genes in Hepatocellular Carcinoma Based on Weighted Gene Co-expression Network and Cancer Genome Atlas Clinical Data [J]. Chinese General Practice, 2024, 27(32): 4050-4059. |
[14] | MAIERHABA· Maimaitiaili, ZHANG Kainan, ZHAO Hui, YAKUFU· Tuoheti, YE Jianwei, LYU Guodong. Investigating Serum PARP2 as a Potential Diagnostic Biomarker for Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(32): 4060-4065. |
[15] | HU Lingxi, LI Mei, FU Yiwei, LU Lixia, MA Xiaoxuan, WANG Rongqi, NAN Yuemin. The Value of Serum VEGF in Evaluating the Clinical Efficacy of TACE Alone or Combined with Target Immunotherapy in Advanced Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(32): 4033-4039. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||